Jun 23, 2008 by Brian LawlerWait a Little Longer, LigandThe FDA delays its review of blood-disorder drug Promacta.
Jun 18, 2008 by Brian LawlerElan's and Wyeth's Data: Success or Failure?The results for a drug for Alzheimer's aren't conclusive.
Jun 17, 2008 by Brian LawlerExelixis Gets Special TreatmentThe FDA clarifies goals for a thyroid cancer drug that's in testing.
Jun 13, 2008 by Brian LawlerLilly Patches Its PipelineAn early-stage compound joins the pharmaceutical's upcoming roster.
Jun 13, 2008 by Brian LawlerNovo Nordisk Bleeds a LittleThe pharmaceutical's hot streak ends as a vital study fizzles out.
Jun 13, 2008 by Brian LawlerGlaxo Gears Up a BlockbusterOne of the pharmaceutical's top new compounds scores final EU approval.
Jun 12, 2008 by Brian LawlerGilead's Got the GoodsChecking in with the promising pharmaceutical company.
Jun 11, 2008 by Brian LawlerPain and King Start the CountdownWho will win the race to get approval of an abuse-deterrent drug?
Jun 11, 2008 by Brian LawlerHe Said, Biogen SaidThe pharmaceutical's battle with Carl Icahn is coming to a head.
Jun 10, 2008 by Brian LawlerBuy Back Shares, Then Issue More?American Oriental Bioengineering has strange timing.
Jun 10, 2008 by Brian LawlerVertex Doesn't DisappointThe pharmaceutical's lead drug continues to ace its tests.
Jun 10, 2008 by Brian LawlerExelixis Secures Its FutureThe drugmaker pulls off a creative, clever approach to raising cash.
Jun 10, 2008 by Brian LawlerAllergan's Unblemished DealAcquiring a niche acne drug from QLT provides clarity for both companies.
Jun 9, 2008 by Brian LawlerNovo Nordisk's Daring SuccessA potential blockbuster compound excels in late-stage head-to-head testing.
Jun 6, 2008 by Brian LawlerNothing Can Stop Novartis!The pharmaceutical giant digests another drugmaker.
Jun 6, 2008 by Brian LawlerSorry, Sanofi: More Bad NewsThe pharmaceutical's top drug prospect is linked to more side effects.
Jun 5, 2008 by Brian LawlerCancer Concerns Fuel FDA InquiryThe agency examines a class of blockbuster drugs for a link to cancer in young patients.
